The Gene Fix That's Rewriting a Death Sentence for Kids

FDA approves Kresladi, a one-time gene therapy for LAD-I, a rare immune disorder that once left children with few options and little hope

1 May 2026

For children born with Leukocyte Adhesion Deficiency Type I, the diagnosis has long amounted to a countdown. Now, for the first time, there is something to stop it.

On March 26, 2026, the FDA approved Kresladi, a first-of-its-kind gene therapy developed by Rocket Pharmaceuticals. The treatment targets LAD-I, a rare genetic disorder in which white blood cells cannot reach infected tissue, leaving the body defenseless against illness from the first months of life. Fewer than 25 children are diagnosed in the United States each year, and without treatment, many do not survive early childhood.

A matched sibling transplant can be curative, but compatible donors are scarce. Most families never find one. Kresladi was built for those families.

The therapy's mechanics are precise: doctors harvest the patient's own stem cells, correct the faulty gene in a lab, and return the repaired cells in a single infusion. No donor required. No permanent immune suppression. In a clinical trial of nine children aged five months to nine years, every participant survived to the 12-month mark. Severe infections dropped sharply. Wound healing improved. No serious treatment-related side effects were recorded.

The FDA granted accelerated approval on the strength of those results, with long-term data collection ongoing. Rocket also received a Rare Pediatric Disease Priority Review Voucher, a transferable regulatory asset with significant market value that signals investor confidence in the company's pipeline.

The approval lands at a defining moment for rare disease medicine. New FDA frameworks designed to fast-track therapies for ultra-rare genetic conditions are reshaping the orphan drug landscape, and Kresladi is among the clearest proof that those frameworks can work. The agency's willingness to move quickly for a condition affecting so few children reflects a regulatory culture finally catching up to scientific possibility.

For parents who had been told there was nothing left to try, that shift is everything. A single infusion, and the countdown stops.